 Home > Biochemistry News > Biotechnology News > Fate announces new data on CAR-NK therapy

Fate announces new data on CAR-NK therapy

 Last Update: 2021-09-13
 Source: Internet
 Author: User

Tags

cancer killing drug

sv40 large antigen

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

news

A few days ago, the American biotechnology company Fate announced the results of phase I clinical dose climbing of its induced pluripotent stem cell (iPSC) modified NK cell therapy FT516 and CAR-NK therapy FT596
.

Eight of 11 lymphoma patients responded with different doses of FT516, and six of them were CR

Drug source analysis

This result is quite good, roughly the same as the allogeneic CAR-T.
One of the main reasons for Fate's decline is its 9 billion market value
.

Previously, Fate only announced the data of 4 clinical patients, but because activated NK and CAR-NK are new treatments, investors have been full of strings and gave the most optimistic valuation

Unlike CAR-T, which relies on T cells, Fate's technology uses NK cells from the natural immune system
.

Fate's NK cells do not come from patients or healthy donors, but through iPSC differentiation technology

Only two of the four so-called highly malignant patients who are resistant to CAR-T have responded, which makes investors worry that CAR-NK does not have much advantage over allogeneic CAR-T in terms of efficacy
.

Although FT516 is not a CAR-NK, it has a similar structure.

Although CAR-T has a higher response rate in certain hematological tumors, durability and safety are issues that need to be resolved
.

Cell therapies similarly designed using other immune cells such as CAR-NK and CAR-M (macrophages) have recently begun to enter the clinic

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.